Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CING | Cingulate Inc.

Index	-	P/E	-	EPS (ttm)	-1.68	Insider Own	2.30%	Shs Outstand	11.70M	Perf Week	4.41%
Market Cap	11.89M	Forward P/E	-	EPS next Y	-0.65	Insider Trans	482.72%	Shs Float	10.67M	Perf Month	8.34%
Income	-19.30M	PEG	-	EPS next Q	-0.49	Inst Own	2.30%	Short Float / Ratio	7.26% / 1.46	Perf Quarter	-22.16%
Sales	-	P/S	-	EPS this Y	44.10%	Inst Trans	-50.07%	Short Interest	0.77M	Perf Half Y	-29.41%
Book/sh	-0.52	P/B	-	EPS next Y	64.90%	ROA	-196.60%	Target Price	6.50	Perf Year	-36.84%
Cash/sh	0.02	P/C	39.65	EPS next 5Y	-	ROE	-	52W Range	0.48 - 1.93	Perf YTD	-28.00%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-62.69%	Beta	-0.61
Dividend %	-	Quick Ratio	0.20	Sales past 5Y	-	Gross Margin	-	52W Low	48.48%	ATR	0.07
Employees	15	Current Ratio	0.20	Sales Q/Q	-	Oper. Margin	-	RSI (14)	59.10	Volatility	10.91% 11.08%
Optionable	No	Debt/Eq	-	EPS Q/Q	-58.40%	Profit Margin	-	Rel Volume	0.62	Prev Close	0.76
Shortable	Yes	LT Debt/Eq	-	Earnings	Aug 14 AMC	Payout	-	Avg Volume	529.06K	Price	0.72
Recom	2.00	SMA20	9.96%	SMA50	11.75%	SMA200	-23.06%	Volume	329,423	Change	-5.26%

Sep-21-23 01:30PM	Cingulate Inc. to Present at the LD Micro Main Event XVI (GlobeNewswire)
11:23AM	Cingulate Inc. To Present at the LD Micro Main Event XVI (Newsfile)
Sep-15-23 07:58AM	Cingulate raises $4M from public offering of almost 7M shares (American City Business Journals) +5.57%
Sep-13-23 04:15PM	Cingulate Announces Closing of $4.0 Million Public Offering (GlobeNewswire)
Sep-11-23 09:22AM	Cingulate Announces Pricing of $4.0 Million Public Offering (GlobeNewswire)
06:00AM	Loading…
06:00AM	Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD (GlobeNewswire)
Sep-08-23 04:31PM	Werth Family Investment Associates Converts $5.8 Million of Debt into Cingulate Equity at a Premium (GlobeNewswire)
Sep-05-23 08:00AM	Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023 (GlobeNewswire)
Aug-14-23 04:15PM	Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update (GlobeNewswire)
Jul-27-23 06:25AM	Cingulate Slides As Insider Purchases Lose Another US$45k (Simply Wall St.) -7.51%
Jul-11-23 08:00AM	Cingulate Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD (GlobeNewswire) -8.11%
Jun-29-23 08:00AM	Cingulate Successfully Manufactures Clinical Supply Initiation of Pediatric Phase 3 Studies to Commence in July and August (GlobeNewswire)
Jun-14-23 03:45PM	Cingulate to Participate in the Healthcare Virtual Conference Part II Presented by Maxim Group and Hosted by M-Vest (GlobeNewswire)
Jun-08-23 07:00AM	Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD (GlobeNewswire)
May-25-23 03:55PM	Cingulate to Present at 13th Annual LD Micro Invitational (GlobeNewswire) -5.39%
03:45PM	Loading…
May-12-23 03:45PM	Cingulate, Indegene to Participate in Benzinga All Live Access Event (GlobeNewswire)
May-10-23 04:15PM	Cingulate Inc. Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update (GlobeNewswire)
May-05-23 11:51AM	Breakeven On The Horizon For Cingulate Inc. (NASDAQ:CING) (Simply Wall St.)
May-03-23 06:45AM	Cingulate Announces Successful Transfer of CTx-1301 (dexmethylphenidate) Proprietary PTR Manufacturing Processes to Societal CDMO (GlobeNewswire)
Apr-14-23 02:00PM	Cingulate to Participate in Benzinga All Live Access Event (GlobeNewswire)
Apr-04-23 06:45AM	Cingulate Completes First Cohort of Phase 3 Adult Onset and Duration Trial of CTx-1301 (dexmethylphenidate) for ADHD (GlobeNewswire)
Mar-13-23 06:45AM	Cingulate and Indegene Announce Joint Commercialization Agreement for Lead ADHD Candidate CTx-1301 (GlobeNewswire) -28.65%
Mar-10-23 04:05PM	Cingulate Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Business Update (GlobeNewswire) +25.00%
Feb-24-23 10:19AM	Why Cingulate Shares Are Trading Higher Today (Benzinga) +40.54%
07:04AM	Cingulate stock skyrockets after ADHD treatment shows positive trial results (MarketWatch)
Feb-23-23 04:30PM	Cingulate Announces Positive Top-Line Results from Fed/Fast Study of Lead Asset CTx-1301 for ADHD (GlobeNewswire)
Feb-22-23 06:56AM	Daily Vickers Top Insider Picks for 02/22/2023 (Argus Research)
Feb-21-23 07:35AM	Daily Vickers Top Insider Picks for 02/21/2023 (Argus Research)
Feb-17-23 06:27AM	Daily Vickers Top Insider Picks for 02/17/2023 (Argus Research)
Feb-16-23 07:28AM	Daily Vickers Top Insider Picks for 02/16/2023 (Argus Research) -8.61%
07:01AM	Loading…
Feb-15-23 07:01AM	Daily Vickers Top Insider Picks for 02/15/2023 (Argus Research)
Feb-14-23 06:23AM	Daily Vickers Top Insider Picks for 02/14/2023 (Argus Research)
Feb-13-23 07:30AM	Daily Vickers Top Insider Picks for 02/13/2023 (Argus Research) +25.52%
Jan-09-23 08:25AM	Cingulate begins Phase 3 tests of novel treatment for ADHD (American City Business Journals) -10.80%
Jan-04-23 06:45AM	Cingulate Kickstarts First Phase 3 Trial For ADHD Candidate, Data Expected In First Half 2023 (Benzinga)
06:45AM	Cingulate Initiates Phase 3 Study of Lead Asset CTx-1301, Designed as a True Entire Active-Day Treatment for ADHD (GlobeNewswire)
Dec-01-22 02:00PM	Cingulate Benzinga All Live Access Appearance Rescheduled for December 16 (GlobeNewswire)
Nov-30-22 03:00PM	Cingulate to Participate in Benzinga All Live Access Event (GlobeNewswire) +7.42%
Nov-14-22 06:45AM	Cingulate Inc. Reports Third Quarter 2022 Financial Results and Provides Clinical and Business Update (GlobeNewswire)
Nov-03-22 07:00AM	Cingulate Inc. to Present at Investor Summit Group's Q4 Conference (Newsfile)
Nov-01-22 09:02AM	Cingulate Completes Fed/Fast Study Assessing Food Effect with CTx-1301, Lead Candidate for Treatment of ADHD (GlobeNewswire)
Oct-25-22 07:55AM	Cingulate Shares Fall After Timeline Update For Its Lead Candidate In ADHD (Benzinga)
Oct-24-22 04:45PM	Cingulate Announces Agreement with Societal CDMO and Provides Clinical Update (GlobeNewswire) -6.25%
Oct-20-22 02:20PM	Cingulate to Present at LD Micro Investor Conference (GlobeNewswire)
Sep-19-22 06:45AM	Cingulate Presents Data for Its Triple-Release Buspirone Product Candidate: CTx-2103 (GlobeNewswire) -5.43%
Aug-26-22 07:46AM	Here's Why Cingulate (NASDAQ:CING) Must Use Its Cash Wisely (Simply Wall St.)
Aug-15-22 06:34PM	Cingulate to Participate in Benzinga All Live Access Event (GlobeNewswire) -5.45%
Aug-11-22 06:45AM	Cingulate Inc. Reports Second Quarter 2022 Financial Results and Provides Clinical and Business Update (GlobeNewswire) -9.70%
Jul-25-22 01:45PM	Kansas City Business Journal Names Cingulates Louis G. Van Horn a 2022 Chief Financial Officer of the Year (GlobeNewswire)
Jun-23-22 07:00AM	Cingulate Announces Completion of CTx-2103 Human Formulation Study for the Treatment of Anxiety Disorders (GlobeNewswire)
Jun-21-22 08:43AM	UPDATE -- Diamond Equity Research to Host Emerging Growth Invitational Virtual Investor Conference on June 23, 2022 (GlobeNewswire)
Jun-17-22 12:45PM	Cingulate to Present at Diamond Equity Research 2022 Virtual Emerging Growth Invitational (GlobeNewswire) +10.02%
Jun-02-22 02:40PM	Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event (GlobeNewswire)
May-24-22 06:45AM	Cingulate Announces Complete Enrollment in Human Formulation Study of CTx-2103 for the Treatment of Anxiety Disorders (GlobeNewswire) -6.61%
May-19-22 03:15PM	Cingulate wants to be the next Eli Lilly and stay in Kansas City (American City Business Journals)
May-18-22 05:20PM	Cingulate to Present at H.C. Wainwright Global Investment Conference (GlobeNewswire)
May-12-22 04:15PM	Cingulate Inc. Reports First Quarter 2022 Results and Provides Clinical and Business Update (GlobeNewswire) -6.09%
Apr-26-22 12:27PM	Cingulate Presents at NobleCon18 (GlobeNewswire)
Mar-10-22 06:45AM	Cingulate Inc. Reports Fourth Quarter and Full Year 2021 Results and Provides Clinical and Business Update (GlobeNewswire) -9.85%
Feb-15-22 06:45AM	Cingulate to Present at Aegis Virtual Conference (GlobeNewswire)
Feb-08-22 12:20PM	Cingulate Outlines Plan For Pivotal Attention Deficit/Hyperactivity Disorder Studies (Benzinga) -9.29%
06:45AM	Cingulate Provides 2022 Clinical Plan for CTx-1301, an Investigational Medication for Attention Deficit/Hyperactivity Disorder (ADHD) (GlobeNewswire)
Jan-25-22 06:45AM	Cingulate Appoints Curt Medeiros and Gregg Givens to Board of Directors (GlobeNewswire) +7.94%
Dec-13-21 08:45AM	Cingulate completes $25M IPO, becomes KC area's newest public company (American City Business Journals) -16.03%
Dec-10-21 11:45AM	Aegis Capital Corp. acted as Lead Bookrunning Manager on a $25 Million Initial Public Offering of Common Stock for Cingulate Inc. (NASDAQ: CING) (ACCESSWIRE) -5.40%
11:00AM	Cingulate Inc. Announces Closing of Initial Public Offering (GlobeNewswire)
Dec-07-21 09:05PM	Cingulate Inc. Announces Pricing of $25.0 Million Initial Public Offering (GlobeNewswire)

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders intended for children, adolescents, and adults. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Callahan Jennifer L.	Corporate Controller	Sep 15	Buy	0.67	5,000	3,348	45,508	Sep 18 06:00 PM
Werth Peter J.	Director	Aug 11	Buy	0.55	1,823,155	1,000,001	2,798,320	Aug 14 04:38 PM
Callahan Jennifer L.	Corporate Controller	May 15	Buy	1.01	2,000	2,020	40,508	May 16 06:00 PM
Callahan Jennifer L.	Corporate Controller	May 12	Buy	1.08	4,000	4,320	38,508	May 16 06:00 PM
Schaffer Shane J.	Chief Executive Officer	Dec 16	Buy	1.02	10,000	10,166	41,500	Dec 19 05:03 PM
Schaffer Shane J.	Chief Executive Officer	Dec 14	Buy	1.01	13,267	13,400	31,500	Dec 15 06:00 PM
Callahan Jennifer L.	Corporate Controller	Dec 14	Buy	0.99	7,548	7,468	34,508	Dec 15 06:00 PM
Werth Peter J.	Director	Dec 13	Buy	0.98	28,934	28,422	975,165	Dec 15 06:00 PM
Schaffer Shane J.	Chief Executive Officer	Dec 13	Buy	1.01	1,733	1,750	18,233	Dec 15 06:00 PM
Callahan Jennifer L.	Corporate Controller	Nov 29	Buy	0.98	1,530	1,499	26,960	Nov 30 05:00 PM
Callahan Jennifer L.	Corporate Controller	Nov 28	Buy	0.98	3,487	3,417	25,430	Nov 30 05:00 PM
Gilgallon Craig S.	EVP, GC and Secretary	Nov 23	Buy	0.84	3,575	3,003	9,550	Nov 28 05:00 PM
Myers Laurie	EVP and COO	Nov 23	Buy	0.90	1,111	1,000	48,263	Dec 01 05:00 PM
GIVENS GREGG WM	Director	Nov 22	Buy	0.88	85,000	74,851	154,318	Nov 25 05:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CING | Cingulate Inc.

Upgrade your FINVIZ experience